This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schetelig, J. Articles by Siegert, W. Search for Related Content PubMed PubMed Citation Articles by Schetelig, J. Articles by Siegert, W. Social Bookmarking                            What's this?

Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study Group

J. Schetelig, C. Thiede, M. Bornhäuser, R. Schwerdtfeger, M. Kiehl, J. Beyer, H.G. Sayer, N. Kröger, M. Hensel, C. Scheffold, T.K. Held, K. Höffken, A.D. Ho, J. Kienast, A. Neubauer, A.R. Zander, A.A. Fauser, G. Ehninger, W. Siegert

From the Charité Campus Virchow Klinikum and Klinik für Innere Medizin m.S. Hämatologie und Onkologie; Charité Campus Mitte, Humboldt-Universität zu Berlin, Medizinische Klinik II m.S. Onkologie und Hämatologie, Berlin; Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden; Stiftung Deutsche Klinik für Diagnostik GmbH, Zentrum für Blutstammzell-und Knochenmarktransplantation, Wiesbaden; Klinik für Knochenmark-transplantation und Hämatologie/Onkologie GmbH, Idar-Oberstein; Klinikum der Philipps-Universität, Abteilung für Innere Medizin Hämatologie/Onkologie/Immunologie, Marburg; Friedrich Schiller Universität Jena, Klinik für Innere Medizin II; Universitäts-Krankenhaus Eppendorf, Medizinische Klinik Knochenmarktransplantation, Hamburg; Universität Heidelberg, Medizinische Klinik und Poliklinik, Abteilung Innere Medizin V, Hämatologie, Onkologie und Rheumatologie; and Westfälische Wilhelms-Universität, Medizinische Klinik, Innere Medizin A, Münster, Germany.

Address reprint requests to Wolfgang Siegert, MD, Medizinische KIinik II mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Charité Mitte, Schumannstr. 20–21, 10117 Berlin, Germany; email: wolfgang.siegert{at}charite.de.

Purpose: To study whether hematopoietic stem-cell transplantation (HSCT) after reduced-intensity conditioning is effective and tolerable in patients with advanced chronic lymphocytic leukemia (CLL).

Patients and Methods: Thirty patients with advanced B-cell CLL were included into the study. After reduced-intensity conditioning with fludarabine, busulfan, and antithymocyte globulin, patients received a transplant from related (n = 15) or unrelated donors (n = 15). Minimal residual disease (MRD) was monitored with a clone-specific polymerase chain reaction.

Results: After a median follow-up of 2 years, 23 patients are alive (to date). Neutrophil and platelet engraftment occurred after a median of 17.5 and 15 days, respectively. Acute graft-versus-host disease (GVHD) grade 2 to 4 was observed in 17 patients (56%), and chronic GVHD was observed in 21 patients (75%). Twelve patients (40%) achieved a complete remission (CR), and 16 patients (53%) achieved a partial remission. Late CR occurred up to 2 years after transplantation. MRD was monitored in eight patients with CR. All patients achieved a molecular CR. At last follow-up, six patients were in ongoing molecular CR. Causes of death were treatment-related complications in four patients and progressive disease in three patients. The probability of overall survival, progression-free survival, and nonrelapse mortality at 2 years was 72% (95% confidence interval [CI], 54% to 90%), 67% (95% CI, 49% to 85%), and 15% (95% CI, 1% to 29%), respectively.

Conclusion: Treatment-related mortality after reduced-intensity conditioning followed by allogeneic HSCT was low. The procedure induced molecular remissions in patients with advanced CLL. The observation of late remissions provided evidence of a graft-versus-leukemia effect.

Supported by the Deutsche Krebshilfe (70-2755; C.T.,M.B.).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. Marina, U. Hainz, M. A. Biernacki, W. Zhang, A. Cai, J. S. Duke-Cohan, F. Liu, V. Brusic, D. Neuberg, J. L. Kutok, et al. Serologic Markers of Effective Tumor Immunity against Chronic Lymphocytic Leukemia Include Nonmutated B-Cell Antigens Cancer Res., February 15, 2010; 70(4): 1344 - 1355. [Abstract] [Full Text] [PDF]

				J. Delgado, D. W. Milligan, and P. Dreger Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, September 24, 2009; 114(13): 2581 - 2588. [Abstract] [Full Text] [PDF]

				S. Stilgenbauer, T. Zenz, D. Winkler, A. Buhler, R. F. Schlenk, S. Groner, R. Busch, M. Hensel, U. Duhrsen, J. Finke, et al. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group J. Clin. Oncol., August 20, 2009; 27(24): 3994 - 4001. [Abstract] [Full Text] [PDF]

				T. Nishida, M. Hudecek, A. Kostic, M. Bleakley, E. H. Warren, D. Maloney, R. Storb, and S. R. Riddell Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia Clin. Cancer Res., July 15, 2009; 15(14): 4759 - 4768. [Abstract] [Full Text] [PDF]

				L. Farina, C. Carniti, A. Dodero, A. Vendramin, A. Raganato, F. Spina, F. Patriarca, F. Narni, F. Benedetti, A. Olivieri, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation Haematologica, May 1, 2009; 94(5): 654 - 662. [Abstract] [Full Text] [PDF]

				P. Dreger Allotransplantation for chronic lymphocytic leukemia Hematology, January 1, 2009; 2009(1): 602 - 609. [Abstract] [Full Text] [PDF]

				J. Schetelig, A. van Biezen, R. Brand, D. Caballero, R. Martino, M. Itala, J. A. Garcia-Marco, L. Volin, N. Schmitz, R. Schwerdtfeger, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis J. Clin. Oncol., November 1, 2008; 26(31): 5094 - 5100. [Abstract] [Full Text] [PDF]

				M. L. Sorror, B. E. Storer, B. M. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. R. Chauncey, M. A. Pulsipher, P. A. McSweeney, et al. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning J. Clin. Oncol., October 20, 2008; 26(30): 4912 - 4920. [Abstract] [Full Text] [PDF]

				M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood, June 15, 2008; 111(12): 5446 - 5456. [Abstract] [Full Text] [PDF]

				M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF]

				I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies Blood, October 15, 2007; 110(8): 2931 - 2939. [Abstract] [Full Text] [PDF]

				A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF]

				C. Kahl, B. E. Storer, B. M. Sandmaier, M. Mielcarek, M. B. Maris, K. G. Blume, D. Niederwieser, T. R. Chauncey, S. J. Forman, E. Agura, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood, October 1, 2007; 110(7): 2744 - 2748. [Abstract] [Full Text] [PDF]

				J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF]

				J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, et al. T lymphocytes redirected against the {kappa} light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells Blood, December 1, 2006; 108(12): 3890 - 3897. [Abstract] [Full Text] [PDF]

				K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF]

				S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood, March 15, 2006; 107(6): 2578 - 2584. [Abstract] [Full Text] [PDF]

				E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch How I treat refractory CLL Blood, February 15, 2006; 107(4): 1276 - 1283. [Abstract] [Full Text] [PDF]

				J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study Blood, February 15, 2006; 107(4): 1724 - 1730. [Abstract] [Full Text] [PDF]

				B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF]

				C. Nabhan and J. D. Bitran Chronic Lymphocytic Leukemia: To Transplant or Not to Transplant... That Is the Question? J. Clin. Oncol., November 1, 2005; 23(31): 8126 - 8127. [Full Text] [PDF]

				D. Caballero, J. A. Garcia-Marco, R. Martino, V. Mateos, J. M. Ribera, J. Sarra, A. Leon, G. Sanz, J. de la Serna, R. Cabrera, et al. Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-) Clin. Cancer Res., November 1, 2005; 11(21): 7757 - 7763. [Abstract] [Full Text] [PDF]

				S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research J. Clin. Oncol., August 20, 2005; 23(24): 5788 - 5794. [Abstract] [Full Text] [PDF]

				M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF]

				C. Moreno, N. Villamor, D. Colomer, J. Esteve, R. Martino, J. Nomdedeu, F. Bosch, A. Lopez-Guillermo, E. Campo, J. Sierra, et al. Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., May 20, 2005; 23(15): 3433 - 3438. [Abstract] [Full Text] [PDF]

				F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror, R. Diaconescu, A. E. Woolfrey, T. R. Chauncey, M. E.D. Flowers, M. Mielcarek, et al. Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning J. Clin. Oncol., March 20, 2005; 23(9): 1993 - 2003. [Abstract] [Full Text] [PDF]

				M. Ritgen, S. Stilgenbauer, N. von Neuhoff, A. Humpe, M. Bruggemann, C. Pott, T. Raff, A. Krober, D. Bunjes, R. Schlenk, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR Blood, October 15, 2004; 104(8): 2600 - 2602. [Abstract] [Full Text] [PDF]

				U. Schuler Reduced intensity conditioning before allografting: moderate enthusiasm may be more appropriate Eur. Respir. J., March 1, 2004; 23(3): 357 - 358. [Full Text] [PDF]

				M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF]